Renhe Pharmacy Co

Renhe Pharmacy Co CROIC

The Cash Return on Invested Capital (CROIC) of Renhe Pharmacy Co (000650.SZ) as of Oct 28, 2026 is 12.30 %. In the previous year, Cash Return on Invested Capital (CROIC) was 4.40 % — a change of 179.70% (higher).

CROIC

12.30 %

YoY

179.70%

Last updated:

Cash Return on Invested Capital (CROIC) of Renhe Pharmacy Co is 2025 12.30 % . Cash Return on Invested Capital (CROIC) of Renhe Pharmacy Co was 2024 4.40 % . It decreases by 179.70% higher compared to the previous year.

The Renhe Pharmacy Co CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
14.72 CNY
Jan 1, 2019
14.74 CNY
Jan 1, 2020
12.71 CNY
Jan 1, 2021
5.22 CNY
Jan 1, 2022
18.16 CNY
Jan 1, 2023
5.21 CNY
Jan 1, 2024
4.40 CNY
Jan 1, 2025
12.30 CNY
The Renhe Pharmacy Co CROIC history
YEARCROICYoY
12.30 %+179.70%
4.40 %-15.53%
5.21 %-71.34%
18.16 %+247.74%
5.22 %-58.90%
12.71 %-13.75%
14.74 %+0.09%
14.72 %-2.50%
15.10 %-10.09%
16.79 %+12.28%
14.96 %+33.53%
11.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renhe Pharmacy Co Stock analysis

What does Renhe Pharmacy Co do? Renhe Pharmacy Co., Ltd. generates revenue through the manufacturing and distribution of pharmaceutical products including capsules, granules, tablets, powder, injections, suppositories, and ointment. The company operates in the domestic market, focusing on medical industrial manufacturing and medical merchandising. Its primary customers are domestic healthcare providers and retail outlets purchasing health-related products for distribution or direct consumer use. The firm's product portfolio spans various dosage forms essential for medical treatment and patient care. The company's business model relies on both wholesale and retail channels within China, serving the domestic pharmaceutical market. Renhe Pharmacy's manufacturing segment produces a wide range of medication forms, while its merchandising division handles the sale of health-related products. This dual approach allows the company to capture value across the pharmaceutical supply chain from production to consumer. Renhe Pharmacy Co., Ltd. serves the Chinese domestic market exclusively, with its operations centered on medical industrial manufacturing and medical merchandising. The company's revenue streams are derived from the sale of its diverse product range to healthcare institutions, pharmacies, and consumers through its retail network. This integrated approach ensures consistent market presence and customer reach within its geographic focus. Renhe Pharmacy Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renhe Pharmacy Co stock

Cash Return on Invested Capital (CROIC) of Renhe Pharmacy Co is 12.30 % in 2025.

Cash Return on Invested Capital (CROIC) of Renhe Pharmacy Co changed from 4.40 % to 12.30 %, representing a 179.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Renhe Pharmacy Co since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Renhe Pharmacy Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Renhe Pharmacy Co

All Key Metrics — Renhe Pharmacy Co